GlassScriptPhysician profile
Miranda K Gruenberg
NPI 1841444734
$4,230.25
in general payments reported to CMS, 2019-2025
26 companies · $180 in 2025
The $180 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,149 · 2022: $878 · 2023: $325 · 2024: $698 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,203.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,085.62 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $938.27 | 2021 | |
| Novo Nordisk INC | $542.75 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $379.15 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $261.36 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $124.99 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $90.41 | 2021-2022 | |
| Lilly USA, LLC | $86.43 | 2021-2024 | Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $77.79 | 2024-2025 | Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $66.52 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $65.97 | 2021-2022 | |
| Abbott Laboratories | $62.35 | 2022 | |
| Cranial Technologies, INC | $62.01 | 2021-2024 | Doc Band |
| Sanofi Pasteur INC. | $61.76 | 2021-2022 | |
| Amarin Pharma, INC. | $50.04 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $49.16 | 2024-2025 | |
| Currax Pharmaceuticals LLC | $42.19 | 2022 | |
| Allergan, INC. | $29.99 | 2021 | |
| Supernus Pharmaceuticals, INC. | $28.73 | 2021-2022 | |
| Upsher-Smith Laboratories LLC | $22.14 | 2021 | |
| Merck Sharp & Dohme LLC | $20.60 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.70 | 2022 | |
| Sobi, INC | $17.58 | 2021 | |
| Amgen INC. | $16.92 | 2021 | |
| Horizon Therapeutics Plc | $16.20 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miranda Gruenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.